Zebrafish in Neurotoxicity Screening: A Predictive Model for Safer Drug Development

Neurotoxicity is a major concern in drug development, as compounds that interfere with the nervous system can lead to severe side effects ranging from cognitive impairment to neurodegeneration. Traditional mammalian models remain indispensable, but they are resource-intensive, time-consuming, and not always predictive of human outcomes. In recent years, zebrafish have emerged as a powerful complementary system, offering unique advantages for early-stage neurotoxicity screening. With their transparent embryos, conserved vertebrate biology, and measurable behavioral endpoints, zebrafish provide a predictive and scalable model that bridges the gap between in vitro assays and mammalian studies.

Why Zebrafish Are a Reliable Model for Neurotoxicity Screening

Zebrafish share over 70% of human genes, with more than 80% of human disease-related genes having a zebrafish ortholog. This high degree of conservation translates into comparable neuronal pathways, neurotransmitter systems, and brain structures, making zebrafish particularly suitable for neurotoxicology research. Dopaminergic, glutamatergic, and cholinergic systems in zebrafish show similar pharmacological responses to those in mammals. 

Figure 1. Conserved zebrafish brain and human brain structures. 

Their optical transparency during embryonic and larval stages allows direct in vivo imaging of neuronal development, apoptosis, demyelination, and axonal integrity using fluorescent markers and immunostaining. Drug-induced injuries in the optic nerve can be visualized, as well as motor neurons or dopaminergic circuits in real time, enabling a more comprehensive understanding of neurotoxic mechanisms.

Another critical advantage lies in their rapid development and external fertilization. Within 72 hours post-fertilization, zebrafish larvae have a fully functional nervous system capable of producing quantifiable behavioral responses. Coupled with high fecundity and small size, these features make the zebrafish model ideal for high-throughput assays, reducing the reliance on mammalian testing while aligning with the 3Rs principle (replacement, reduction, refinement) in animal research. 

Zebrafish-Based Assays and Behavioral Endpoints in Neurotoxicity Screening

One of the most valuable aspects of zebrafish in neurotoxicity screening is their wide repertoire of measurable behaviors when coupled to an automated tracking system. Larvae acquire the startle reflex response to tactile, visual, and auditory stimuli within 5 days post-fertilization, providing a unique window into how compounds affect the nervous system at functional levels.

Locomotor activity is the most widely used behavioral endpoint. Automated video tracking allows to detect subtle alterations in swimming patterns, such as hypoactivity, hyperactivity, or erratic movements, which often serve as early indicators of neuronal dysfunction. Light-dark transition tests, in which larvae respond to sudden changes in illumination, are another standard paradigm. The light-dark transition increases locomotor activity, while the dark-light transition decreases it. Pattern changes reveal anxiety-like behaviors and altered arousal states, both of which can be disrupted by neuroactive or neurotoxic compounds, as can be seen in Figure 2. 

Figure 2. General motor activity evaluation. Light/Dark locomotion pattern of zebrafish larvae in response to a negative control, a neurotoxic agent (positive control), and a study compound that doesn’t produce neurotoxicity effects on basal locomotor activity.

Startle response assays provide further sensitivity. When exposed to an acoustic or vibrational stimulus, zebrafish larvae display a stereotyped escape movement. Neurotoxicants that impair sensorimotor circuits reduce the frequency, latency, or amplitude of this reflex, offering a reliable endpoint for toxicity screening. Similarly, seizure assays using convulsant agents such as pentylenetetrazole (PTZ) reproduce electrophysiological and behavioral seizure patterns observed in mammals, enabling rapid assessment of pro-convulsant or anti-seizure drug effects. 

In adults, a broader range of behavioral tests expands the screening possibilities. Novel tank diving tests measure stress and anxiety responses by assessing fish behavior in a new environment. Anxiety-related behavior is characterized by freezing events and time spent at the tank’s bottom, while boldness behavior corresponds to greater distance covered in the upper tank area. For example, the administration of metformin, methamphetamine, and acrylamide reduces the time spent in the upper area of the tank. Other tests, such as mirror biting and social preference assays, capture aggression and sociability, both of which can be altered by neurotoxic exposures.

The strength of these behavioral assays lies in their scalability and translational value. They can be conducted in multi-well plates with high-throughput imaging platforms, such as the Daniovision™ device together with the Ethovision XT software (Noldus IT), generating quantifiable and reproducible datasets. More importantly, many behavioral changes observed in zebrafish parallel those seen in mammalian models and even in clinical contexts, making them predictive tools for early safety decisions.

Applications of Zebrafish Models in Predicting Drug-Induced Neurotoxicity

The practical applications of zebrafish in neurotoxicity assessment are increasingly recognized by both academia and industry. Their utility spans several domains of drug safety evaluation.

One major application is in early-phase drug discovery, where zebrafish serve as a cost-effective tool to identify neurotoxic liabilities before compounds advance to mammalian studies. Because exposure is often achieved by dissolving test compounds directly in water, hundreds of molecules can be rapidly screened with minimal material. This approach helps filter out high-risk candidates and reduces the number of mammals needed for follow-up testing.

Zebrafish also serve to identify potential molecular drug targets, since neurologic-associated genes are conserved in zebrafish. Finally, zebrafish are also used to model human neurodegenerative conditions and predict drug-induced neurotoxicity that could exacerbate such disorders. Studies have demonstrated their ability to replicate hallmarks of Parkinson’s, Alzheimer’s, and motor neuron diseases, providing insight into both disease mechanisms and adverse drug effects. 

Its enormous potential for evaluating neurotoxic compounds in a predictive and reliable way has led to the development of zebrafish platforms for neurotoxicity screening. 

→ NeuroTox is an assay based on transgenic zebrafish larvae expressing green fluorescent protein (GFP) in a neuronal transgenic reporter. They are incubated with 1-5 concentrations of the compound of interest to measure neurotoxicity and central nervous system side effects (according to the exposure timeframe). We measure:

• Locomotor activity in response to light/dark cycles. 
• Changes in neuronal number. 
• Seizures, thigmotaxis, and sedation. 

If you're interested in learning more about how the zebrafish neurotoxicity assay can fit into your preclinical pipeline, contact us!

References

Cassar S, Adatto I, Freeman JL, Gamse JT, Iturria I, Lawrence C, Muriana A, Peterson RT, Van Cruchten S, Zon LI. Use of Zebrafish in Drug Discovery Toxicology. Chem Res Toxicol. 2020 Jan 21;33(1):95-118. doi: 10.1021/acs.chemrestox.9b00335.

Kozol RA, Abrams AJ, James DM, Buglo E, Yan Q, Dallman JE. Function Over Form: Modeling Groups of Inherited Neurological Conditions in Zebrafish. Front Mol Neurosci. 2016 Jul 7;9:55. doi: 10.3389/fnmol.2016.00055.

Parng C, Roy NM, Ton C, Lin Y, McGrath P. Neurotoxicity assessment using zebrafish. J Pharmacol Toxicol Methods. 2007 Jan-Feb;55(1):103-12. doi: 10.1016/j.vascn.2006.04.004.

Toni M, Arena C, Cioni C, Tedeschi G. Temperature- and chemical-induced neurotoxicity in zebrafish. Front Physiol. 2023 Oct 3;14:1276941. doi: 10.3389/fphys.2023.1276941.

By Miriam Martínez

Miriam is a Human Biologist with a strong background in neuropharmacology and a passion for bridging science and innovation. After earning a master’s degree in the Pharmaceutical and Biotech Industry, she completed her PhD in Biomedicine at Pompeu Fabra University (Barcelona), where her research focused on the behavioral analysis of animal models for neurophenotypical characterization. Following her doctoral studies, Miriam transitioned into the healthcare marketing and communication sector, where she played a key role in developing impactful marketing strategies and educational campaigns for leading pharmaceutical brands. She now leverages her scientific expertise, strategic thinking, and creative communication skills in her current role at ZeClinics.